The VMTH does not recommend administering
different vaccine antigens at separate time points because it reduces the chance that vaccines will be administered and there is poor evidence that it decreases the risk of reactions occurring.
Not exact matches
While the 3D injectable scaffold is being tested in mice as a potential cancer
vaccine, any combination of
different antigens and drugs could be loaded into the scaffold, meaning it could also be used to treat infectious diseases that may be resistant to conventional treatments.
This service will allow users to improve the compatibility and stability of their
vaccine antigen with
different mucosal adjuvants (from the HZI portfolio) and to define the optimal production methods to generate immunogenic
vaccine candidates with optimised physicochemical stability (in vitro studies).
Firstly, it will develop optimised viral vectors suitable for expressing
antigens from a range of
different diseases, to create novel
vaccines.
The department has developed and produced 15
different formulations for early clinical trials (e.g.
vaccine antigens produced by heterologous expression) and has conducted more than 20 clinical trials as sponsor.
The service «Expression of
vaccine antigens in plant - based systems» can be requested as a standalone service, or in the context of the «Cross-platform screening and optimization service» which enabled the user to have
vaccine antigens expressed in several
different platforms with the aim to compare yields, integrity and (if possible) functionality of the protein when produced in
different systems.
The body may be resistant to the
vaccine if the
antigens are markedly
different from the tumor or if the immune system of the patient has been severely weakened through other treatments, such as chemotherapy.
The
vaccine inoculation often includes several
different disease
antigens combined into one injection dose.
Highly motivated scientist and experienced who has been investigating
different aspects of the immune response to malaria
vaccines and other parasite
antigens.
Le, T.P., Church, L.W.P., Corradin, G., Hunter, R.L., Charoenvit, Y., Wang, R., de la Vega, P., Sacci, J., Ballou, W.R., Kolodny, N., Kitov, S., Glenn, G.M., Richards, R. L., Alving, C.R., Hoffman, S.L. Immunogenicity of Plasmodium falciparum circumsporozoite protein multiple
antigen peptide
vaccine formulated with
different adjuvants.